1 / 6

Benign Prostatic Hyperplasia Therapeutics Industry Expected to Witness a Sustainable Growth

The global benign prostatic hyperplasia therapeutics market was valued at $10,688.72 million in 2017, and is projected to reach $20,096.68 million by 2025 at a CAGR of 8.1% from 2018 to 2025.

newmarketindustry
Télécharger la présentation

Benign Prostatic Hyperplasia Therapeutics Industry Expected to Witness a Sustainable Growth

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Benign Prostatic Hyperplasia Therapeutics Industry

  2. A rise in the male geriatric population is the major factor that surges the demand of benign prostatic hyperplasia drugs for treatment of the enlarged prostate gland. This enlargement of the prostate gland is characterized by partial or complete urinary tract obstruction, finally inhibiting the normal flow of urine. Moreover, growth in awareness for prostate cancer and other urological disorders is expected to boost the demand of benign prostatic hyperplasia therapeutics. Benign Prostatic Hyperplasia Therapeutics Market was valued at $10,689 million in 2017, and is projected to reach $20,097 million in 2025, registering a CAGR of 8.1% from 2018 to 2025. Get Sample Report

  3. Benign prostatic hyperplasia (BPH) is a medical condition in which a males prostate gland size increases abnormally. This condition results in problems to start urination, weak urine stream, inability to empty the urinary bladder, and enhanced urine frequency usually at night. BPH therapeutics are drugs categorized into three different classes namely, alpha blocker, 5-alpha reductase inhibitor, and phosphodiesterase-5 inhibitor. These drugs relax the smooth bladder muscles or shrink the abnormal prostate growth to alleviate the BHP symptoms. The relaxation of the muscles of the bladder loosens the prostates grip on the urethra facilitating urine to flow more freely. Whereas, the shrinkage of the size of the prostate reduces the pressure exerted by the prostate on the urethra, resulting in free flow of urine.

  4. Increasing prevalence of benign prostatic hyperplasia, rising global geriatric population, and soaring awareness related to urological disorders and prostate cancer across the world are the factors that drive the global benign prostatic hyperplasia therapeutics market growth. However, higher adoption rate of minimally-invasive surgical therapies instead of BPH therapeutics is expected to impede the market growth. Conversely, high market potential in the untapped emerging economies and presence of several pipeline products are expected to provide many opportunities during the forecast period.

  5. Key findings of the Benign Prostatic Hyperplasia Therapeutics Market: • The phosphodiesterase-5 inhibitor segment accounted for nearly one-sixth share of the global benign prostatic hyperplasia therapeutics market in 2017. • The mono drug therapy segment is expected to grow at a CAGR of 7.6% from 2018 to 2025. • Europe accounted for around one-third share of the global market in 2017. • LAMEA is expected to provide lucrative market growth opportunities and grow at a CAGR of 9.6% from 2018 to 2025.

  6. The key players of the global benign prostatic hyperplasia therapeutics market include Abbott Laboratories, Allergan plc, Astellas Pharma, Inc., Boehringer Ingelheim Pharma GmbH & Co. KG, Eli Lilly and Company, GlaxoSmithKline plc, Merck & Co., Inc., Pfizer, Inc., Sanofi, and Teva Pharmaceutical Industries Limited. Other players (these players are not profiled in the report and the same can be included on request) in the value chain include Nymox Pharmaceutical Corporation, Protox Therapeutics, Inc., ternaZentaris, and Urologix, LLC.

More Related